| 1.265 -0.055 (-4.17%) | 03-05 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.79 |
1-year : | 2.03 |
| Resists | First : | 1.53 |
Second : | 1.73 |
| Pivot price | 1.34 |
|||
| Supports | First : | 1.21 | Second : | 1 |
| MAs | MA(5) : | 1.32 |
MA(20) : | 1.39 |
| MA(100) : | 1.64 |
MA(250) : | 3.66 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1  |
| %K %D | K(14,3) : | 23.8 |
D(3) : | 25.3 |
| RSI | RSI(14): 38.8 |
|||
| 52-week | High : | 11.64 | Low : | 1.21 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ INMB ] has closed above bottom band by 14.6%. Bollinger Bands are 47.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.33 - 1.34 | 1.34 - 1.35 |
| Low: | 1.24 - 1.25 | 1.25 - 1.26 |
| Close: | 1.25 - 1.27 | 1.27 - 1.28 |
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; and XPro1595 for the treatment of Alzheimer's disease. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.
Tue, 03 Mar 2026
Inmune Bio (INMB): Why This Beaten-Down Small-Cap Is Back on Risk Radars - AD HOC NEWS
Fri, 27 Feb 2026
INmune Bio (NASDAQ: INMB) outlines RDEB and Alzheimer’s trial paths - Stock Titan
Mon, 23 Feb 2026
INmune Bio Inc. Announces Webinar on XPro1595 Registrational Pathway for Early Alzheimer's Disease Treatment - Quiver Quantitative
Mon, 23 Feb 2026
Alzheimer’s therapy XPro1595 nears key trial as INmune Bio details Phase 3 path - Stock Titan
Thu, 19 Feb 2026
INmune Bio to Host Feb. 26 Webinar Presenting MissionEB Phase III CORDStrom Data - TradingView
Tue, 27 Jan 2026
Alzheimer’s trial signal and rare skin disease cell therapy at INmune Bio - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 27 (M) |
| Held by Insiders | 2.061e+007 (%) |
| Held by Institutions | 18.7 (%) |
| Shares Short | 3,240 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -69 % |
| Return on Assets (ttm) | 724 % |
| Return on Equity (ttm) | -50.6 % |
| Qtrly Rev. Growth | 50000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -207.7 |
| EBITDA (p.s.) | 66666.7 |
| Qtrly Earnings Growth | -2.1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -31 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 0.99 |
| Dividend | 0 |
| Forward Dividend | 4.05e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|